{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:28:14Z","timestamp":1793089694946,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,3,31]],"date-time":"2012-03-31T00:00:00Z","timestamp":1333152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s10147-012-0396-6","type":"journal-article","created":{"date-parts":[[2012,3,29]],"date-time":"2012-03-29T21:16:35Z","timestamp":1333055795000},"page":"1-9","source":"Crossref","is-referenced-by-count":156,"title":["Malignant ascites: pathophysiology and treatment"],"prefix":"10.1007","volume":"18","author":[{"given":"Emanuel","family":"Cavazzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Bugiantella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"Graziosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Silvia","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annibale","family":"Donini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,31]]},"reference":[{"issue":"2","key":"396_CR1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/clon.2002.0135","volume":"15","author":"EM Smith","year":"2003","unstructured":"Smith EM, Jayson GC (2003) The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 15(2):59\u201372 (review)","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"396_CR2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4103\/0256-4947.55167","volume":"29","author":"MW Saif","year":"2009","unstructured":"Saif MW, Siddiqui IA, Sohail MA (2009) Management of ascites due to gastrointestinal malignancy. Ann Saudi Med 29(5):369\u2013377 (review)","journal-title":"Ann Saudi Med"},{"key":"396_CR3","doi-asserted-by":"crossref","unstructured":"Keen A, Fitzgerald D, Bryant A et al (2010) Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev (1):CD007794 (review)","DOI":"10.1002\/14651858.CD007794.pub2"},{"issue":"6","key":"396_CR4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","volume":"198","author":"RA Adam","year":"2004","unstructured":"Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198(6):999\u20131011 (review)","journal-title":"J Am Coll Surg"},{"issue":"4","key":"396_CR5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","volume":"6","author":"BK Zebrowski","year":"1999","unstructured":"Zebrowski BK, Liu W, Ramirez K et al (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6(4):373\u2013378","journal-title":"Ann Surg Oncol"},{"key":"396_CR6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0065-2571(94)00022-U","volume":"35","author":"PD Brown","year":"1995","unstructured":"Brown PD (1995) Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 35:293\u2013301","journal-title":"Adv Enzyme Regul"},{"issue":"3","key":"396_CR7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0885-3924(94)00129-9","volume":"10","author":"S Sharma","year":"1995","unstructured":"Sharma S, Walsh D (1995) Management of symptomatic malignant ascites with diuretics: two case reports and a review of the literature. J Pain Symptom Manag 10(3):237\u2013242 (review)","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"396_CR8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0885-3924(98)00037-2","volume":"16","author":"CW Lee","year":"1998","unstructured":"Lee CW, Bociek G, Faught W (1998) A survey of practice in management of malignant ascites. J Pain Symptom Manag 16(2):96\u2013101","journal-title":"J Pain Symptom Manag"},{"issue":"4","key":"396_CR9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/0016-5085(92)91520-E","volume":"103","author":"PJ Pockros","year":"1992","unstructured":"Pockros PJ, Esrason KT, Nguyen C et al (1992) Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 103(4):1302\u20131306","journal-title":"Gastroenterology"},{"issue":"1","key":"396_CR10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/bjs.1800830104","volume":"83","author":"SL Parsons","year":"1996","unstructured":"Parsons SL, Watson SA, Steele RJ (1996) Malignant ascites. Br J Surg 83(1):6\u201314 (review)","journal-title":"Br J Surg"},{"key":"396_CR11","unstructured":"Covey AM (2005) Management of malignant pleural effusions and ascites. J Support Oncol 3(2):169\u2013173, 176 (review)"},{"issue":"1","key":"396_CR12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1191\/026921600676345896","volume":"14","author":"P McNamara","year":"2000","unstructured":"McNamara P (2000) Paracentesis\u2014an effective method of symptom control in the palliative care setting? Palliat Med 14(1):62\u201364","journal-title":"Palliat Med"},{"issue":"2","key":"396_CR13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0016-5085(87)91007-9","volume":"93","author":"P Gin\u00e9s","year":"1987","unstructured":"Gin\u00e9s P, Arroyo V, Quintero E et al (1987) Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 93(2):234\u2013241","journal-title":"Gastroenterology"},{"issue":"6","key":"396_CR14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0016-5085(88)90691-9","volume":"94","author":"P Gin\u00e8s","year":"1988","unstructured":"Gin\u00e8s P, Tit\u00f3 L, Arroyo V et al (1988) Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94(6):1493\u20131502","journal-title":"Gastroenterology"},{"issue":"1","key":"396_CR15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0168-8278(87)80067-3","volume":"5","author":"F Salerno","year":"1987","unstructured":"Salerno F, Badalamenti S, Incerti P et al (1987) Repeated paracentesis and i.v. albumin infusion to treat \u2018tense\u2019 ascites in cirrhotic patients. A safe alternative therapy. J Hepatol 5(1):102\u2013108","journal-title":"J Hepatol"},{"issue":"8429","key":"396_CR16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(85)92147-6","volume":"1","author":"E Quintero","year":"1985","unstructured":"Quintero E, Gin\u00e9s P, Arroyo V et al (1985) Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet 1(8429):611\u2013612","journal-title":"Lancet"},{"issue":"3","key":"396_CR17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jpainsymman.2008.09.008","volume":"38","author":"ND Fleming","year":"2009","unstructured":"Fleming ND, Alvarez-Secord A, Von Gruenigen V et al (2009) Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manag 38(3):341\u2013349 (review)","journal-title":"J Pain Symptom Manag"},{"issue":"4","key":"396_CR18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1051-0443(07)61740-0","volume":"13","author":"TD Barnett","year":"2002","unstructured":"Barnett TD, Rubins J (2002) Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites: a simplified percutaneous approach. J Vasc Interv Radiol 13(4):379\u2013383","journal-title":"J Vasc Interv Radiol"},{"key":"396_CR19","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/01.RVI.0000136828.42612.B4","volume":"15","author":"S Rosenberg","year":"2004","unstructured":"Rosenberg S, Courtney A, Nemcek AA et al (2004) Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol 15:1129\u20131131","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"396_CR20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1055\/s-2007-992328","volume":"24","author":"LS Stokes","year":"2007","unstructured":"Stokes LS (2007) Percutaneous management of malignant fluid collections. Semin Interv Radiol 24(4):398\u2013408. doi: 10.1055\/s-2007-992328","journal-title":"Semin Interv Radiol"},{"issue":"5","key":"396_CR21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","volume":"42","author":"G Becker","year":"2006","unstructured":"Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42(5):589\u2013597 (review)","journal-title":"Eur J Cancer"},{"issue":"18","key":"396_CR22","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.1955.02960350004002","volume":"159","author":"AS Weisberger","year":"1955","unstructured":"Weisberger AS, Levine B, Storaasli JP (1955) Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 159(18):1704\u20131707","journal-title":"J Am Med Assoc"},{"issue":"4","key":"396_CR23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jso.2930200411","volume":"20","author":"P Appelqvist","year":"1982","unstructured":"Appelqvist P, Silvo J, Salmela L et al (1982) On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? J Surg Oncol 20(4):238\u2013242","journal-title":"J Surg Oncol"},{"issue":"5","key":"396_CR24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/02841866809133211","volume":"7","author":"AP Andersen","year":"1968","unstructured":"Andersen AP, Brincker H (1968) Intracavitary thiotepa in malignant pleural and peritoneal effusions. Acta Radiol Ther Phys Biol 7(5):369\u2013378","journal-title":"Acta Radiol Ther Phys Biol"},{"key":"396_CR25","first-page":"90","volume":"28","author":"HP Groesbeck","year":"1962","unstructured":"Groesbeck HP, Cudmore JT (1962) Intracavitary thio-TEPA for malignant effusions. Am Surg 28:90\u201395","journal-title":"Am Surg"},{"issue":"2","key":"396_CR26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/oxfordjournals.annonc.a058762","volume":"5","author":"AL Jones","year":"1994","unstructured":"Jones AL, Trott P, Cunningham D et al (1994) A pilot study of intraperitoneal cisplatin in the management of gastric cancer. Ann Oncol 5(2):123\u2013126","journal-title":"Ann Oncol"},{"issue":"7","key":"396_CR27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF01225271","volume":"118","author":"M Markman","year":"1992","unstructured":"Markman M, Kelsen D (1992) Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118(7):547\u2013550","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"396_CR28","first-page":"567","volume":"40","author":"JL Speyer","year":"1980","unstructured":"Speyer JL, Collins JM, Dedrick RL et al (1980) Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40(3):567\u2013572","journal-title":"Cancer Res"},{"issue":"12","key":"396_CR29","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1200\/JCO.1990.8.12.2054","volume":"8","author":"RL Schilsky","year":"1990","unstructured":"Schilsky RL, Choi KE, Grayhack J et al (1990) Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 8(12):2054\u20132061","journal-title":"J Clin Oncol"},{"issue":"8","key":"396_CR30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5694\/j.1326-5377.1980.tb131916.x","volume":"2","author":"RF Kefford","year":"1980","unstructured":"Kefford RF, Woods RL, Fox RM et al (1980) Intracavitary adriamycin nitrogen mustard and tetracycline in the control of malignant effusions: a randomized study. Med J Aust 2(8):447\u2013448","journal-title":"Med J Aust"},{"key":"396_CR31","first-page":"310","volume":"40","author":"JM Trotter","year":"1979","unstructured":"Trotter JM, Stuart JFB, McBeth F et al (1979) The management of malignant effusions with bleomycin. Br J Cancer 40:310","journal-title":"Br J Cancer"},{"issue":"1","key":"396_CR32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/1097-0142(19820701)50:1<62::AID-CNCR2820500113>3.0.CO;2-0","volume":"50","author":"M Katano","year":"1982","unstructured":"Katano M, Torisu M (1982) Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50(1):62\u201368","journal-title":"Cancer"},{"issue":"3","key":"396_CR33","first-page":"357","volume":"93","author":"M Torisu","year":"1983","unstructured":"Torisu M, Katano M, Kimura Y et al (1983) New approach to management of malignant ascites with a streptococcal preparation, OK-432. Improvement of host immunity and prolongation of survival. Surgery 93(3):357\u2013364","journal-title":"Surgery"},{"issue":"4","key":"396_CR34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000010320","volume":"50","author":"DM Sherer","year":"2000","unstructured":"Sherer DM, Eliakim R, Abulafia O (2000) The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest 50(4):217\u2013224 (review)","journal-title":"Gynecol Obstet Invest"},{"issue":"5","key":"396_CR35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/10799900050023933","volume":"20","author":"B Stoelcker","year":"2000","unstructured":"Stoelcker B, Echtenacher B, Weich HA et al (2000) VEGF\/Flk-1 interaction, a requirement for malignant ascites recurrence. J Interferon Cytokine Res 20(5):511\u2013517","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"396_CR36","first-page":"579","volume":"5","author":"V Gebbia","year":"1991","unstructured":"Gebbia V, Russo A, Gebbia N et al (1991) Intracavitary beta-interferon for the management of pleural and\/or abdominal effusions in patients with advanced cancer refractory to chemotherapy. In Vivo 5(6):579\u2013581","journal-title":"In Vivo"},{"issue":"5D","key":"396_CR37","first-page":"3917","volume":"18","author":"M Katano","year":"1998","unstructured":"Katano M, Morisaki T (1998) The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 18(5D):3917\u20133925 (review)","journal-title":"Anticancer Res"},{"issue":"5B","key":"396_CR38","first-page":"2201","volume":"15","author":"Y Yamaguchi","year":"1995","unstructured":"Yamaguchi Y, Satoh Y, Miyahara E et al (1995) Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res 15(5B):2201\u20132206","journal-title":"Anticancer Res"},{"issue":"8","key":"396_CR39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/1097-0142(196608)19:8<1096::AID-CNCR2820190808>3.0.CO;2-N","volume":"19","author":"IM Ariel","year":"1966","unstructured":"Ariel IM, Oropeza R, Pack GT (1966) Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. Cancer 19(8):1096\u20131102","journal-title":"Cancer"},{"issue":"12","key":"396_CR40","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/1097-0142(19811215)48:12<2596::AID-CNCR2820481210>3.0.CO;2-J","volume":"48","author":"GL Jackson","year":"1981","unstructured":"Jackson GL, Blosser NM (1981) Intracavitary chromic phosphate (32P) colloidal suspension therapy. Cancer 48(12):2596\u20132598","journal-title":"Cancer"},{"issue":"5","key":"396_CR41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/bjc.1988.280","volume":"58","author":"B Ward","year":"1988","unstructured":"Ward B, Mather S, Shepherd J et al (1988) The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. Br J Cancer 58(5):658\u2013662","journal-title":"Br J Cancer"},{"issue":"1","key":"396_CR42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0090-8258(92)90084-V","volume":"47","author":"R Buckman","year":"1992","unstructured":"Buckman R, De Angelis C, Shaw P et al (1992) Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 47(1):102\u2013109","journal-title":"Gynecol Oncol"},{"issue":"12","key":"396_CR43","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","volume":"14","author":"S Kobold","year":"2009","unstructured":"Kobold S, Hegewisch-Becker S, Oechsle K et al (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12):1242\u20131251 (review)","journal-title":"Oncologist"},{"issue":"18 Suppl","key":"396_CR44","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1200\/jco.2007.25.18_suppl.9043","volume":"25","author":"K El-Shami","year":"2007","unstructured":"El-Shami K, Elsaid A, El-Kerm Y (2007) Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol 25(18 Suppl):9043","journal-title":"J Clin Oncol"},{"issue":"1\u20133","key":"396_CR45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006119319695","volume":"52","author":"PD Brown","year":"1998","unstructured":"Brown PD (1998) Matrix metalloproteinase inhibitors. Breast Cancer Res Treat 52(1\u20133):125\u2013136 (review)","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"396_CR46","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0748-7983(97)93077-8","volume":"23","author":"SL Parsons","year":"1997","unstructured":"Parsons SL, Watson SA, Steele RJ (1997) Phase I\/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 23(6):526\u2013531","journal-title":"Eur J Surg Oncol"},{"issue":"15","key":"396_CR47","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","volume":"19","author":"SR Bramhall","year":"2001","unstructured":"Bramhall SR, Rosemurgy A, Brown PD, Marimastat Pancreatic Cancer Study Group et al (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19(15):3447\u20133455","journal-title":"J Clin Oncol"},{"issue":"1B","key":"396_CR48","first-page":"639","volume":"23","author":"J King","year":"2003","unstructured":"King J, Zhao J, Clingan P et al (2003) Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 23(1B):639\u2013645","journal-title":"Anticancer Res"},{"issue":"6","key":"396_CR49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","volume":"36","author":"D Seimetz","year":"2010","unstructured":"Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM\u00a0\u00d7\u00a0anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36(6):458\u2013467 (review)","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"396_CR50","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","volume":"13","author":"A Burges","year":"2007","unstructured":"Burges A, Wimberger P, K\u00fcmper C et al (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM\u00a0\u00d7\u00a0anti-CD3 antibody: a phase I\/II study. Clin Cancer Res 13(13):3899\u20133905","journal-title":"Clin Cancer Res"},{"issue":"9","key":"396_CR51","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer 127(9):2209\u20132221","journal-title":"Int J Cancer"},{"issue":"6","key":"396_CR52","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ejso.2006.03.014","volume":"32","author":"A Garofalo","year":"2006","unstructured":"Garofalo A, Valle M, Garcia J et al (2006) Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 32(6):682\u2013685","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"396_CR53","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.gassur.2006.01.011","volume":"10","author":"A Knutsen","year":"2006","unstructured":"Knutsen A, Sielaff TD, Greeno E et al (2006) Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. J Gastrointest Surg 10(7):1038\u20131043","journal-title":"J Gastrointest Surg"},{"issue":"2","key":"396_CR54","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejso.2007.05.015","volume":"34","author":"E Facchiano","year":"2008","unstructured":"Facchiano E, Scaringi S, Kianmanesh R et al (2008) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 34(2):154\u2013158","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"396_CR55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","volume":"100","author":"M Valle","year":"2009","unstructured":"Valle M, Van der Speeten K, Garofalo A et al (2009) Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol 100(4):331\u2013334","journal-title":"J Surg Oncol"},{"issue":"5","key":"396_CR56","first-page":"237","volume":"30","author":"L Graziosi","year":"2009","unstructured":"Graziosi L, Bugiantella W, Cavazzoni E et al (2009) Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report. G Chir 30(5):237\u2013239","journal-title":"G Chir"},{"issue":"1","key":"396_CR57","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1245\/s10434-007-9571-9","volume":"15","author":"A Gesson-Paute","year":"2008","unstructured":"Gesson-Paute A, Ferron G, Thomas F et al (2008) Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol 15(1):339\u2013344","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"396_CR58","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","volume":"249","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Saxena A et al (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249(6):900\u2013907 (review)","journal-title":"Ann Surg"},{"issue":"1","key":"396_CR59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejso.2010.11.004","volume":"37","author":"M Deraco","year":"2011","unstructured":"Deraco M, Baratti D, Laterza B et al (2011) Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol 37(1):4\u20139 (review)","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"396_CR60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.03.004","volume":"113","author":"A Fagotti","year":"2009","unstructured":"Fagotti A, Paris I, Grimolizzi F et al (2009) Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol 113(3):335\u2013340","journal-title":"Gynecol Oncol"},{"issue":"2","key":"396_CR61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jso.21448","volume":"101","author":"JH Kim","year":"2010","unstructured":"Kim JH, Lee JM, Ryu KS et al (2010) Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol 101(2):149\u2013155","journal-title":"J Surg Oncol"},{"issue":"12","key":"396_CR62","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","volume":"14","author":"S Kobold","year":"2009","unstructured":"Kobold S, Hegewisch-Becker S, Oechsle K et al (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12):1242\u20131251 (review)","journal-title":"Oncologist"},{"issue":"5","key":"396_CR63","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejso.2010.01.006","volume":"36","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Quenet F et al (2010) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 36(5):456\u2013462","journal-title":"Eur J Surg Oncol"},{"issue":"36","key":"396_CR64","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27(36):6237\u20136242","journal-title":"J Clin Oncol"},{"issue":"1","key":"396_CR65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10120-011-0016-6","volume":"14","author":"H Imamoto","year":"2011","unstructured":"Imamoto H, Oba K, Sakamoto J et al (2011) Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced\/recurrent gastric cancer. Gastric Cancer 14(1):81\u201390","journal-title":"Gastric Cancer"},{"issue":"7","key":"396_CR66","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jjco\/hyi109","volume":"35","author":"N Oriuchi","year":"2005","unstructured":"Oriuchi N, Nakajima T, Mochiki E et al (2005) A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol 35(7):386\u2013390","journal-title":"Jpn J Clin Oncol"},{"key":"396_CR67","doi-asserted-by":"crossref","first-page":"890758","DOI":"10.1155\/2011\/890758","volume":"2011","author":"F Bellati","year":"2011","unstructured":"Bellati F, Napoletano C, Gasparri ML et al (2011) Monoclonal antibodies in gynecological cancer: a critical point of view. Clin Dev Immunol 2011:890758","journal-title":"Clin Dev Immunol"},{"issue":"6","key":"396_CR68","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11912-011-0199-3","volume":"13","author":"M Hall","year":"2011","unstructured":"Hall M, Rustin G (2011) Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep 13(6):459\u2013471 (review)","journal-title":"Curr Oncol Rep"},{"key":"396_CR69","doi-asserted-by":"crossref","unstructured":"Tappenden P, Jones R, Paisley S et al (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 11(12):1\u2013128, III\u2013IV (review)","DOI":"10.3310\/hta11120"},{"issue":"7","key":"396_CR70","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1517\/14712598.2011.582464","volume":"11","author":"CR Garrett","year":"2011","unstructured":"Garrett CR, Eng C (2011) Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 11(7):937\u2013949 (review)","journal-title":"Expert Opin Biol Ther"},{"key":"396_CR71","doi-asserted-by":"crossref","unstructured":"Dotan E, Meropol NJ, Burtness B et al (2012) A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer [Epub ahead of print]","DOI":"10.1007\/s12029-012-9368-3"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0396-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-012-0396-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0396-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T22:08:18Z","timestamp":1593900498000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-012-0396-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,31]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1007\/s10147-012-0396-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,31]]}}}